ArticleBMC cancer2026
Prognostic significance of pretreatment pan-immune inflammation value in esophageal squamous cell carcinoma patients undergoing definitive chemoradiotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe pan-immune inflammation value (PIV) reflects the balance between host immune and inflammatory status and is a commonly used indicator for evaluating cancer prognosis. However, to date, no studies have confirmed the prognostic value of pretreatment PIV in patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing definitive chemoradiotherapy (dCRT).
methodsThe receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value of the PIV for predicting prognosis. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors. Restricted cubic spline (RCS) curve analysis was used to investigate the relationship between PIV and prognosis. A visual analysis was conducted using the SHAP method. Combined with TNM staging, a comprehensive risk stratification model was constructed through recursive partitioning analysis (RPA). Finally, the model was evaluated through decision curve analysis (DCA) and ROC curve.
resultsA total of 696 patients were included. The level of PIV before treatment was significantly correlated with a larger primary tumor burden. RCS analysis revealed a non-linear relationship between PIV and survival outcomes. Both univariate and multivariate Cox analyses confirmed that the pre-treatment PIV was an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Subgroup analysis showed that in all subgroups except those receiving ≥ 3 cycles of chemotherapy, high PIV was an adverse prognostic factor. Based on PIV and TNM stage, a new risk stratification model was constructed through RPA, which classified patients into three risk groups with significantly different OS and PFS. Compared with the traditional TNM stage, this RPA model showed significantly better predictive performance.
conclusionPretreatment PIV is an independent prognostic biomarker in locally advanced ESCC patients undergoing dCRT. The novel RPA model integrating PIV with TNM staging outperforms traditional staging, offering a refined "anatomical-biological" risk stratification tool to guide personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.